Earlier this week, AbbVie strengthened its manufacturing capabilities by breaking ground on a new $223 million expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network.

About the Singapore Plant

Located in Singapore’s Tuas Biomedical Park, AbbVie’s Singapore plant is a small-molecule and biologics manufacturing facility serving markets worldwide. This new investment will add 24,000 liters of biologics drug-substance capacity to AbbVie’s global manufacturing network and support current products as well as emerging immunology and oncology compounds within AbbVie’s pipeline.
 
“This expansion announcement represents one of AbbVie’s many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore,” said Azita Saleki-Gerhardt, Ph.D., AbbVie Executive Vice President, Chief Operations Officer. “The expansion of our Singapore site will strengthen our global manufacturing capabilities, support our growing biologics pipeline and help AbbVie continue delivering on our patient commitments now and in the future.”
 
With this announcement, AbbVie has invested more than $740 million in acquiring, modernizing and expanding its Singapore facility over the past 10 years. When fully operational, the expanded Singapore manufacturing facility – AbbVie’s only manufacturing site in Asia – will employ more than 500 people in manufacturing, quality assurance, supply chain, engineering and administration roles.
 
“We are delighted that AbbVie has chosen to expand its biologics capacity in Singapore for current and future innovative medicines. We are grateful for AbbVie’s continued trust in the strength of Singapore’s biopharmaceutical manufacturing capabilities and talent base. AbbVie’s investment will enhance Singapore’s leading advanced manufacturing ecosystem and create exciting job opportunities here,” said Cindy Koh, Executive Vice President, Singapore Economic Development Board.
 
Construction on the expansion will begin later this year, with operations expected to commence in 2026. AbbVie’s Singapore manufacturing plant is a part of AbbVie’s Operations team, which consists of 14,000 employees working at more than 30 manufacturing, operations and logistics sites across the United States, Asia, Europe, Puerto Rico and South America.

More AbbVie News

AbbVie recently entered a definitive agreement to acquire Cerevel Therapeutics and its neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across schizophrenia, Parkinson’s disease (PD), and mood disorders.